Please login to the form below

Not currently logged in
Email:
Password:

Recipharm appoints chief strategy officer

Jean-François Hilaire will take up the role with immediate effect

Contract development and manufacturing organisation Recipharm has named Jean-François Hilaire as chief strategy officer.

Hilaire is a pharmacist, graduating from the university of Boredeaux, and is additionally alumni of the CEDEP general manager programme.

Commenting on his new role, Hilaire said: “I am glad to be joining Recipharm and its leadership team whom I have had the chance to know for several years and admire their entrepreneurship. 

“Furthermore, with the current transformation of the pharmaceutical industry, I see Recipharm as very well positioned to catch sizable business opportunities in extending the value created for its customers.”

Hilaire brings a broad range of experience to the role, with skills acquired in both commercial and manufacturing and supply leadership roles at Abbott, Solvay and Fournier. 

Thomas Eldered, CEO at Recipharm, commented: “Jean- François Hilaire will bring valuable and relevant experience from the pharmaceutical industry in general but also very important views from outsourcing of pharmaceutical development and manufacturing.”


4th June 2015

From: Sales, Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics